The long term implications of fertility therapy for the health of women

Robert J Norman
Med J Aust 2022; 217 (10): . || doi: 10.5694/mja2.51760
Published online: 21 November 2022

Cardiovascular disease mortality is not increased in women undergoing IVF, but vigilant surveillance is nonetheless required

Since the first birth facilitated by in vitro fertilisation (IVF) in 1978, the use of IVF has spread across the world and more than eight million babies have been born.1 The use of medically assisted reproduction, including IVF, currently accounts for about 7% of all births in Australia, and the annual number of births involving assisted reproductive technology has increased by 55% over the past ten years.2 IVF is a recognised medical technology with a reasonable success rate in younger women, partially funded by Medicare, widely available across Australia, and well accepted by the Australian community.

  • The Robinson Research Institute, the University of Adelaide, Adelaide, SA

Competing interests:

No relevant disclosures.

  • 1. European Society of Human Reproduction and Embryology. Eight million IVF babies since the birth of the world’s first in 1978 [media release]. 4 July 2018.‐News‐GlobalIVF18 (viewed Oct 2022).
  • 2. Choi SKY, Venetis C, Ledger W, et al. Population‐wide contribution of medically assisted reproductive technologies to overall births in Australia: temporal trends and parental characteristics. Hum Reprod 2022; 37: 1047‐1058.
  • 3. Venn A, Hemminki E, Watson L, et al. Mortality in a cohort of IVF patients. Hum Reprod 2001; 16: 2691‐2696.
  • 4. Venn A, Watson L, Lumley J, et al. Breast and ovarian cancer incidence after infertility and in vitro fertilisation. Lancet 1995; 346: 995‐1000.
  • 5. Yiallourou S, Magliano D, Haregu TN, et al. Long term all‐cause and cardiovascular disease mortality among women who undergo fertility treatment. Med J Aust 2022; 217: 532‐537.
  • 6. Sergentanis TN, Diamantaras AA, Perlepe C, et al. IVF and breast cancer: a systematic review and meta‐analysis. Hum Reprod Update 2014; 20: 106‐123.
  • 7. Spaan M, van den Belt‐Dusebout AW, Lambalk CB, et al. Long‐term risk of ovarian cancer and borderline tumors after assisted reproductive technology. J Natl Cancer Inst 2021; 113: 699‐709.
  • 8. Joham AE, Norman RJ, Stener‐Victorin E, et al. Polycystic ovary syndrome. Lancet Diabetes Endocrinol 2022; 10: 668‐680.
  • 9. Moran LJ, Norman RJ, Teede HJ. Metabolic risk in PCOS: phenotype and adiposity impact. Trends Endocrinol Metab 2015; 26: 136‐143.
  • 10. Wang R, Li W, Bordewijk EM, et al. Reproductive Medicine Network; International Ovulation Induction IPDMA Collaboration. First‐line ovulation induction for polycystic ovary syndrome: an individual participant data meta‐analysis. Hum Reprod Update 2019; 25: 717‐732.
  • 11. Gomes JMD, VanHise K, Stachenfeld N, et al. Subclinical cardiovascular disease and polycystic ovary syndrome. Fert Steril 2022; 117: 912‐923.
  • 12. Saito K, Kuwahara A, Ishikawa T, et al. Endometrial preparation methods for frozen‐thawed embryo transfer are associated with altered risks of hypertensive disorders of pregnancy, placenta accrete and gestational diabetes. Hum Reprod 2019; 34: 1567‐1575.
  • 13. Luke B, Brown MB, Eisenberg M, et al. In vitro fertilization and risk for hypertensive disorders of pregnancy: associations with treatment parameters. Am J Obstet Gynecol 2020; 222: 350.e1‐350. e13.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.